t
Proteome Sciences plc announced on 5 January 2023 that Thermo Scientific achieved a cumulative sales milestone under their exclusive licence and distributor agreement. Proteome Sciences plc received a milestone payment of £0.87m, which will be recognised in the 2022 financial year.
| Date | 5 Jan 2023 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 7307L |
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation. With the publication of this announcement, this information is now considered to be in the public domain
5 January 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Milestone Payment for TMT®/TMTpro™ Sales
The Company announces that pursuant to the exclusive licence and distributor agreement with Thermo Scientific, a cumulative sales milestone has been achieved by Thermo Scientific. Pursuant to the sales milestone, a milestone payment of £0.87m has been received by the Company and will be recognised in the 2022 financial year.
For further information please contact:
|
Proteome Sciences plc |
|
|
Dr Mariola Soehngen, Chief Executive Officer |
Tel: +44 (0)20 7043 2116 |
|
Dr Ian Pike, Chief Scientific Officer |
|
|
Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer |
|
|
Allenby Capital Limited (AIM Nominated Adviser & Broker) |
|
|
John Depasquale / Jeremy Porter (Corporate Finance) Tony Quirke (Sales) |
Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.